Browsing Category

S-4 Filing

961 posts
Read More

Phoenix Biotech Files Proxy on CERo Therapeutics Deal

The parties currently expect that the total proceeds upon closing will constitute a majority of the $30 million minimum cash condition and that they will successfully negotiate the reduction or deferral of certain cash expenses payable to third-party vendors at closing.